Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Homeland Security Advisory Council

Executive Summary

Lilly CEO Sidney Taurel named to President Bush's Homeland Security Advisory Council created by executive order March 19...

You may also be interested in...



Lilly’s “shared sense of values”

Lilly CEO Sidney Taurel tells Aug. 29 meeting of President's Homeland Security Advisory Council that running a successful organization requires the creation of "a common culture" resulting from "a sense of shared values." The meeting focused on advice to the Administration on creating a new Homeland Security Department; it featured presentations from corporate executives on strategies for successful integration after mergers. Taurel, from the steadfastly independent Lilly, was appointed to the council in June (1"The Pink Sheet" June 17, In Brief)...

Finance Watch: Two SPAC Deals, Two IPOs Take Four Biopharmas Public

Public Company Edition: Mergers with special purpose acquisition corporations may be heating up, but in addition to the Surrozen and Tango SPAC deals Recursion and Biomea launched initial public offerings. Also, Organon sells $5.6bn worth of notes to fund spinout from Merck & Co.

#ClinicalTrialsSoWhite: How Drug Makers Are Using COVID-19 To Improve Trial Diversity

Efforts to improve trial diversity predate COVID-19, but the pandemic’s disproportionate effects on minority communities have brought the issue to the forefront.

UsernamePublicRestriction

Register

PS040015

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel